# AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

> **NCT00107237** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** AEE788
- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT00107237
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107237, "AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00107237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*